Stephanie Sutherland

565 total citations
17 papers, 379 citations indexed

About

Stephanie Sutherland is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Stephanie Sutherland has authored 17 papers receiving a total of 379 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Stephanie Sutherland's work include HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Stephanie Sutherland is often cited by papers focused on HER2/EGFR in Cancer Research (6 papers), Advanced Breast Cancer Therapies (5 papers) and Cancer Treatment and Pharmacology (5 papers). Stephanie Sutherland collaborates with scholars based in United Kingdom, United States and Cyprus. Stephanie Sutherland's co-authors include S. Ashley, Stephen Johnston, David Miles, Andrew Wardley, N. Davidson, Mohamed Shehata, Stephen Chan, Rashid Bhatti, Sarat Chandarlapaty and Andreas Makris and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Radiology.

In The Last Decade

Stephanie Sutherland

16 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephanie Sutherland United Kingdom 9 203 162 92 84 61 17 379
Ippei Fukada Japan 10 181 0.9× 105 0.6× 50 0.5× 49 0.6× 44 0.7× 38 321
Miguel Gil Gil Spain 8 249 1.2× 135 0.8× 93 1.0× 23 0.3× 28 0.5× 19 367
Andri Papakonstantinou Sweden 11 237 1.2× 198 1.2× 87 0.9× 31 0.4× 28 0.5× 33 419
Binliang Liu China 12 228 1.1× 134 0.8× 134 1.5× 43 0.5× 25 0.4× 34 384
Erion Dobi France 14 217 1.1× 147 0.9× 74 0.8× 22 0.3× 20 0.3× 31 356
Kokoro Kobayashi Japan 11 205 1.0× 106 0.7× 45 0.5× 48 0.6× 18 0.3× 39 341
Stefanos Labropoulos Greece 9 201 1.0× 123 0.8× 59 0.6× 66 0.8× 13 0.2× 13 313
Danilo Galizia Italy 10 179 0.9× 108 0.7× 58 0.6× 22 0.3× 24 0.4× 32 285
Elsa M. Li-Ning-Tapia United States 5 129 0.6× 146 0.9× 78 0.8× 48 0.6× 13 0.2× 6 313
Chiara Fabbroni Italy 7 170 0.8× 117 0.7× 86 0.9× 68 0.8× 16 0.3× 22 272

Countries citing papers authored by Stephanie Sutherland

Since Specialization
Citations

This map shows the geographic impact of Stephanie Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephanie Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephanie Sutherland more than expected).

Fields of papers citing papers by Stephanie Sutherland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephanie Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephanie Sutherland. The network helps show where Stephanie Sutherland may publish in the future.

Co-authorship network of co-authors of Stephanie Sutherland

This figure shows the co-authorship network connecting the top 25 collaborators of Stephanie Sutherland. A scholar is included among the top collaborators of Stephanie Sutherland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephanie Sutherland. Stephanie Sutherland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Okines, Alicia, Jeremy Braybrooke, Iain R. Macpherson, et al.. (2023). Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).. Journal of Clinical Oncology. 41(16_suppl). TPS1111–TPS1111. 2 indexed citations
3.
Jiang, Alice, Lela Buckingham, Faraz Bishehsari, et al.. (2021). Correlation of LINE-1 Hypomethylation With Size and Pathologic Extent of Dysplasia in Colorectal Tubular Adenomas. Clinical and Translational Gastroenterology. 12(6). e00369–e00369. 5 indexed citations
4.
Kosmin, Michael, Anwar R. Padhani, Andrew Gogbashian, et al.. (2020). Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. Radiology. 297(3). 622–629. 22 indexed citations
5.
Sirohi, Bhawna, Marina Parton, Anup Vinayan, et al.. (2020). The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience. Breast Cancer Research and Treatment. 180(3). 809–817. 26 indexed citations
6.
Okines, Alicia, Elisavet Paplomata, Tanya A. Wahl, et al.. (2020). Management of adverse events in patients with HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine (HER2CLIMB).. Journal of Clinical Oncology. 38(15_suppl). 1043–1043. 5 indexed citations
7.
Jiang, Alice, Stephanie Sutherland, Lela Buckingham, & Joshua Melson. (2020). Correlation of LINE-1 hypomethylation with size and dysplasia in colorectal tubular adenomas, and risk for synchronous and metachronous CRC.. Journal of Clinical Oncology. 38(15_suppl). e16083–e16083. 1 indexed citations
8.
Keramida, Kalliopi, Dimitrios Farmakis, Stephanie Sutherland, et al.. (2019). Longitudinal Changes of Right Ventricular Deformation Mechanics During Trastuzumab Therapy in Breast Cancer Patients. European Journal of Heart Failure. 21(4). 529–535. 62 indexed citations
9.
Parton, Marina, Anup Vinayan, Stephanie Sutherland, et al.. (2017). The impact of Oncotype DX breast cancer assay results on clinical practice: A UK experience. Annals of Oncology. 28. v57–v58. 1 indexed citations
10.
Sutherland, Stephanie, David Miles, & Andreas Makris. (2016). Use of maintenance endocrine therapy after chemotherapy in metastatic breast cancer. European Journal of Cancer. 69. 216–222. 14 indexed citations
11.
Hudis, Clifford A., Charles Swanton, Yelena Y. Janjigian, et al.. (2013). A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors. Breast Cancer Research. 15(6). R110–R110. 85 indexed citations
12.
Han, Hyo S., Charles Swanton, Y. Y. Janjigian, et al.. (2011). A phase I study of the AKT inhibitor (MK-2206) with concurrent trastuzumab and lapatinib in patients with HER2-positive solid tumors.. Journal of Clinical Oncology. 29(15_suppl). 3028–3028. 11 indexed citations
13.
Sutherland, Stephanie, S. Ashley, Geraldine Walsh, Ian E. Smith, & Stephen Johnston. (2010). Inflammatory breast cancer—The Royal Marsden Hospital experience. Cancer. 116(S11). 2815–2820. 21 indexed citations
14.
Sutherland, Stephanie, S. Ashley, David Miles, et al.. (2010). Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases – the UK experience. British Journal of Cancer. 102(6). 995–1002. 111 indexed citations
15.
16.
Arnedos, Mónica, Stephanie Sutherland, S. Ashley, & Ian Smith. (2007). Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer. Breast Cancer Research and Treatment. 112(1). 1–4. 4 indexed citations
17.
Sutherland, Stephanie, et al.. (1984). Comparative Evaluation of Cefmenoxime versus Cefoxitinin Serious Infections. The American Journal of Medicine. 77(6). 13–16. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ippei Fukada Breakdown of academic impact, for papers by Miguel Gil Gil Breakdown of academic impact, for papers by Andri Papakonstantinou Breakdown of academic impact, for papers by Binliang Liu Breakdown of academic impact, for papers by Erion Dobi Breakdown of academic impact, for papers by Kokoro Kobayashi Breakdown of academic impact, for papers by Stefanos Labropoulos Breakdown of academic impact, for papers by Danilo Galizia Breakdown of academic impact, for papers by Elsa M. Li-Ning-Tapia Breakdown of academic impact, for papers by Chiara Fabbroni
Rankless by CCL
2026